Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Corey J Langer

Showing results (81-90 of 225) with videos related to

Pageof 23
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594Heather A Wakelee, Wei Wang, Joan H Schiller, et al.
JTO Clinical and Research Reports|May 27, 2024
Brief Report: Long-Term Follow-Up of Adjuvant Pembrolizumab After Locally Ablative Therapy for Oligometastatic NSCLCDavid J Cantor, Christiana Davis, Christine Ciunci, et al.
Annals of Translational Medicine|October 24, 2017
Emerging uses of circulating tumor DNA in advanced stage non-small cell lung cancerMelina Marmarelis, Jeffrey C Thompson, Charu Aggarwal, et al.
Frontiers in Oncology|May 8, 2026
Carboplatin plus pemetrexed versus pemetrexed alone in advanced thymoma and thymic carcinoma: a retrospective cohort studyBenjamin A Bleiberg, Lauren Reed-Guy, Roger B Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2011
Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinomaGirum L Lemma, Ju-Whei Lee, Seena C Aisner, et al.
Cancer|February 8, 2007
A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancerLeena Gandhi, Matthew W Harding, Marcus Neubauer, et al.
Current Medical Research and Opinion|January 30, 2007
Effectiveness versus convenience: patient preferences for an erythropoietic agent to treat cancer-related anemiaCorey J Langer, John M Fastenau, Jamie B Forlenza, et al.
Clinical Lung Cancer|November 14, 2017
Etirinotecan Pegol (NKTR-102) in Third-line Treatment of Patients With Metastatic or Recurrent Non-Small-cell Lung Cancer: Results of a Phase II StudyCharu Aggarwal, Roger B Cohen, Eddy Yu, et al.
International Journal of Radiation Oncology, Biology, Physics|June 2, 2005
Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experienceMitchell Machtay, Chuanchieh Hsu, Ritsuko Komaki, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 5, 2008
Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activityVera Hirsh, Pierre P Major, Allan Lipton, et al.
Pageof 23

Showing results (81-90 of 225) with videos related to

Sort By:
Pageof 23
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594Heather A Wakelee, Wei Wang, Joan H Schiller, et al.
JTO Clinical and Research Reports|May 27, 2024
Brief Report: Long-Term Follow-Up of Adjuvant Pembrolizumab After Locally Ablative Therapy for Oligometastatic NSCLCDavid J Cantor, Christiana Davis, Christine Ciunci, et al.
Annals of Translational Medicine|October 24, 2017
Emerging uses of circulating tumor DNA in advanced stage non-small cell lung cancerMelina Marmarelis, Jeffrey C Thompson, Charu Aggarwal, et al.
Frontiers in Oncology|May 8, 2026
Carboplatin plus pemetrexed versus pemetrexed alone in advanced thymoma and thymic carcinoma: a retrospective cohort studyBenjamin A Bleiberg, Lauren Reed-Guy, Roger B Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2011
Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinomaGirum L Lemma, Ju-Whei Lee, Seena C Aisner, et al.
Cancer|February 8, 2007
A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancerLeena Gandhi, Matthew W Harding, Marcus Neubauer, et al.
Current Medical Research and Opinion|January 30, 2007
Effectiveness versus convenience: patient preferences for an erythropoietic agent to treat cancer-related anemiaCorey J Langer, John M Fastenau, Jamie B Forlenza, et al.
Clinical Lung Cancer|November 14, 2017
Etirinotecan Pegol (NKTR-102) in Third-line Treatment of Patients With Metastatic or Recurrent Non-Small-cell Lung Cancer: Results of a Phase II StudyCharu Aggarwal, Roger B Cohen, Eddy Yu, et al.
International Journal of Radiation Oncology, Biology, Physics|June 2, 2005
Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experienceMitchell Machtay, Chuanchieh Hsu, Ritsuko Komaki, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 5, 2008
Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activityVera Hirsh, Pierre P Major, Allan Lipton, et al.
Pageof 23